Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk

Amyloid-β (Aβ) is secreted as an apolipoprotein of nascent triglyceride-rich lipoproteins (TRL) derived from both liver and intestine, but is better recognized as the principal protein component of senile plaque in subjects with Alzheimer's disease. Recent studies suggest that exaggerated expos...

Full description

Bibliographic Details
Main Authors: Pallebage-Gamarallage, Menuka, Takechi, Ryusuke, Lam, V., Galloway, Susan, Dhaliwal, Satvinder, Mamo, John
Format: Journal Article
Published: Elseiver Ireland Ltd 2010
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/14673
_version_ 1848748685751484416
author Pallebage-Gamarallage, Menuka
Takechi, Ryusuke
Lam, V.
Galloway, Susan
Dhaliwal, Satvinder
Mamo, John
author_facet Pallebage-Gamarallage, Menuka
Takechi, Ryusuke
Lam, V.
Galloway, Susan
Dhaliwal, Satvinder
Mamo, John
author_sort Pallebage-Gamarallage, Menuka
building Curtin Institutional Repository
collection Online Access
description Amyloid-β (Aβ) is secreted as an apolipoprotein of nascent triglyceride-rich lipoproteins (TRL) derived from both liver and intestine, but is better recognized as the principal protein component of senile plaque in subjects with Alzheimer's disease. Recent studies suggest that exaggerated exposure to plasma Aβ can compromise cerebrovascular integrity, resulting thereafter in blood to brain delivery of plasma proteins including TRL-Aβ. Parenchymal deposits of Aβ show significant immunoreactivity to apolipoprotein B (apo B), consistent with the notion of lipoprotein-Aβ entrapment. In wild type mice chronically fed physiologically relevant diets, saturated fats (SFA) enhance chylomicron-Aβ concomitant with disturbances in blood–brain barrier integrity.Similarly, dietary cholesterol promotes cerebrovascular extravasation of apo B lipoprotein-Aβ. In this study, we investigated the effects of Atorvastatin, Pravastatin and Probucol on dietary-fat induced disturbances in BBB function. Atorvastatin, a lipid soluble HMG-CoA reductase inhibitor prevented SFA induced parenchymal extravasation of apo B-Aβ at 28 days when incorporated into the diet at 20 mg/kg. In contrast, Pravastatin a water soluble agent had no effect on BBB integrity at an equivalent dose. In cholesterol supplemented mice, Probucol maintained BBB function and extravasation of apo B-Aβ was not evident. The findings suggest that some lipid-modulating agents may be effective in ameliorating the negative effects of saturated fats and cholesterol on cerebrovascular integrity.
first_indexed 2025-11-14T07:08:59Z
format Journal Article
id curtin-20.500.11937-14673
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T07:08:59Z
publishDate 2010
publisher Elseiver Ireland Ltd
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-146732017-09-13T16:04:40Z Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk Pallebage-Gamarallage, Menuka Takechi, Ryusuke Lam, V. Galloway, Susan Dhaliwal, Satvinder Mamo, John Alzheimer's disease Amyloid-beta Chylomicrons Blood–brain barrier Amyloid-β (Aβ) is secreted as an apolipoprotein of nascent triglyceride-rich lipoproteins (TRL) derived from both liver and intestine, but is better recognized as the principal protein component of senile plaque in subjects with Alzheimer's disease. Recent studies suggest that exaggerated exposure to plasma Aβ can compromise cerebrovascular integrity, resulting thereafter in blood to brain delivery of plasma proteins including TRL-Aβ. Parenchymal deposits of Aβ show significant immunoreactivity to apolipoprotein B (apo B), consistent with the notion of lipoprotein-Aβ entrapment. In wild type mice chronically fed physiologically relevant diets, saturated fats (SFA) enhance chylomicron-Aβ concomitant with disturbances in blood–brain barrier integrity.Similarly, dietary cholesterol promotes cerebrovascular extravasation of apo B lipoprotein-Aβ. In this study, we investigated the effects of Atorvastatin, Pravastatin and Probucol on dietary-fat induced disturbances in BBB function. Atorvastatin, a lipid soluble HMG-CoA reductase inhibitor prevented SFA induced parenchymal extravasation of apo B-Aβ at 28 days when incorporated into the diet at 20 mg/kg. In contrast, Pravastatin a water soluble agent had no effect on BBB integrity at an equivalent dose. In cholesterol supplemented mice, Probucol maintained BBB function and extravasation of apo B-Aβ was not evident. The findings suggest that some lipid-modulating agents may be effective in ameliorating the negative effects of saturated fats and cholesterol on cerebrovascular integrity. 2010 Journal Article http://hdl.handle.net/20.500.11937/14673 10.1016/j.atherosclerosissup.2010.04.002 Elseiver Ireland Ltd restricted
spellingShingle Alzheimer's disease
Amyloid-beta
Chylomicrons
Blood–brain barrier
Pallebage-Gamarallage, Menuka
Takechi, Ryusuke
Lam, V.
Galloway, Susan
Dhaliwal, Satvinder
Mamo, John
Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk
title Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk
title_full Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk
title_fullStr Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk
title_full_unstemmed Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk
title_short Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk
title_sort post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: implications for dementia risk
topic Alzheimer's disease
Amyloid-beta
Chylomicrons
Blood–brain barrier
url http://hdl.handle.net/20.500.11937/14673